Treatment of Pancreatic Cancer With Abraxane

• Status: Completed
• Trial end date: 2020-09-07
• Target enrollment: 0
• Participant gender: All

Summary

This observational program collects data on tolerability, safety and efficacy regarding the use of Abraxane in metastatic pancreatic cancer patients in the daily clinical routine. Additionally data on dosage that is actually used in these patients will be collected. Patients who have pancreatic cancer and additional diseases can be documented in this study, too. Collected data might generate learnings on the optimal use of Abraxane in the daily routine setting.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Celgene; Celgene Corporation
• Treatments: Albumin-Bound Paclitaxel; Gemcitabine; Paclitaxel

Criteria

Inclusion Criteria:

1. Metastatic pancreatic carcinoma

2. Age > 18 years

3. Signed Informed Consent

4. Normal hepatic, renal and Bone Marrow functions

Exclusion Criteria:

1. Pregnant and lactating females 2. Previous treatment for metastatic pancreatic disease

3. Known hypersensitivity to nab-paclitaxel 4. Neutrophils < 1,5 x 10^9/L

-